Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Prescient Therapeutics, Ltd.
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
University of Pittsburgh
Fondazione Italiana Linfomi - ETS
Fondazione Italiana Linfomi - ETS
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
Assistance Publique - Hôpitaux de Paris
Kyowa Kirin Co., Ltd.
SciTech Development, Inc.
City of Hope Medical Center
Barbara Ann Karmanos Cancer Institute
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
Thomas Jefferson University
Lund University Hospital
University College, London
Assistance Publique - Hôpitaux de Paris
4SC AG
Emory University
Peking University First Hospital
Columbia University
Kyowa Kirin Co., Ltd.
European Organisation for Research and Treatment of Cancer - EORTC
Stanford University
Stanford University
National Institutes of Health Clinical Center (CC)
University of Nebraska
University of Nebraska
Eastern Cooperative Oncology Group
Genmab
Stanford University
Genmab
Atara Biotherapeutics
Thomas Jefferson University
Elorac, Inc.
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Fundación Academia Española de Dermatología
4SC AG
Northwestern University
European Organisation for Research and Treatment of Cancer - EORTC
Roswell Park Cancer Institute
AbbVie
Rochester General Hospital
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center